Galectin Therapeutics Inc (NASDAQ: GALT) is -12.40% lower on its value in year-to-date trading and has touched a low of $0.73 and a high of $4.27 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The GALT stock was last observed hovering at around $1.20 in the last trading session, with the day’s loss setting it -0.07%.
Currently trading at $1.13, the stock is -23.29% and -48.08% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.45 million and changing -5.83% at the moment leaves the stock -56.30% off its SMA200. GALT registered -33.14% loss for a year compared to 6-month loss of -51.71%. The firm has a 50-day simple moving average (SMA 50) of $2.1772 and a 200-day simple moving average (SMA200) of $2.58635.
The stock witnessed a -44.74% gain in the last 1 month and extending the period to 3 months gives it a -58.76%, and is -12.40% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.67% over the week and 19.18% over the month.
Galectin Therapeutics Inc (GALT) has around 14 employees, a market worth around $70.41M and $0.00M in sales. Distance from 52-week low is 55.64% and -73.53% from its 52-week high. The company has generated returns on investments over the last 12 months (-2675.95%).
The EPS is expected to grow by 1.35% this year
101.0 institutions hold shares in Galectin Therapeutics Inc (GALT), with institutional investors hold 22.85% of the company’s shares. The shares outstanding are 62.31M, and float is at 43.36M with Short Float at 19.07%. Institutions hold 15.77% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 2.12 million shares valued at $4.78 million. The investor’s holdings represent 3.4143 of the GALT Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 1.56 million shares valued at $3.53 million to account for 2.5232 of the shares outstanding. The other top investors are ADVISOR GROUP HOLDINGS, INC. which holds 1.13 million shares representing 1.8168 and valued at over $2.54 million, while SUSQUEHANNA INTERNATIONAL GROUP, LLP holds 1.5621 of the shares totaling 0.97 million with a market value of $2.19 million.
Galectin Therapeutics Inc (GALT) Insider Activity
The most recent transaction is an insider purchase by Shlevin Harold H., the company’s Director. SEC filings show that Shlevin Harold H. bought 6,500 shares of the company’s common stock on Dec 30 ’24 at a price of $1.16 per share for a total of $7540.0. Following the purchase, the insider now owns 15206.0 shares.
Galectin Therapeutics Inc disclosed in a document filed with the SEC on Dec 23 ’24 that Jamil Khurram (Chief Medical Officer) sold a total of 13,654 shares of the company’s common stock. The trade occurred on Dec 23 ’24 and was made at $0.88 per share for $12044.0. Following the transaction, the insider now directly holds 26346.0 shares of the GALT stock.
Still, SEC filings show that on Dec 23 ’24, LEWIS JOEL (President and CEO) disposed off 56,000 shares at an average price of $0.89 for $49610.0. The insider now directly holds 897,012 shares of Galectin Therapeutics Inc (GALT).
